Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation on Analyst/Investor Meet under Regulation 30 of SEBI Listing Regulation 2015.08-05-2023
08-05-2023
Orchid Pharma Ltd - 524372 - Board Meeting Intimation for To Consider And Approve Audited Financial Results (Standalone & Conso) For Period Ended March 31, 2023
Orchid Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/05/2023 ,inter alia, to consider and approve To consider and approve Audited Financial Results (Standalone & Conso) for period ended March 31, 202303-05-2023
Orchid Pharma Ltd - 524372 - Compliance Certificate Under Regulation 40(10) Of SEBI (LODR) Regulation, 2015
Compliance Certificate under regulation 40(10) of SEBI (LODR) Regulation, 201528-04-2023
Orchid Pharma Ltd - 524372 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyOrchid Pharma Ltd 2CIN NO.L24222TN1992PLC022994 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 143.20 4Highest Credit Rating during the previous FY BBBSTABLE 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CARE RATINGS LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Marina Peter Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: Sunil Kumar Gupta Designation: Chief Financial Officer EmailId: [email protected] Date: 20/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.20-04-2023
Orchid Pharma misses deadline to meet minimum public shareholding rules
In December 2022, Orchid Pharma informed the exchanges that its board has approved raising 500 crore through a qualified institutional placement programme13-04-2023
Orchid Pharma Ltd - 524372 - Compliance Certificate Under Regulation 7(3) Of SEBI(LODR) Regulation 2015
Compliance Certificate Under Regulation 7(3) of SEBI(LODR) Regulation 201512-04-2023
Orchid Pharma Ltd - 524372 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate under Reg. 74(5) of SEBI (DP) Regulation, 2018 for the quarter ended March 31, 2023.12-04-2023
Orchid Pharma Ltd - 524372 - Closure of Trading Window
Intimation of closure of trading window to approve Audited Financial Result for the quarter and year ended March 31, 2023.31-03-2023
Orchid Pharma Ltd - 524372 - Announcement Under Regulation 30 (LODR)- Update
Announcement under Regulation 30 (LODR)- Update03-03-2023